
CAS 2169919-21-3
:Formula:C32H47FN6O4S
InChI:InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
InChI key:FRVSRBKUQZKTOW-UHFFFAOYSA-N
SMILES:CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Revumenib
CAS:Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction.Cost-effective and quality-assured.Formula:C32H47FN6O4SPurity:99.12% - 99.97%Color and Shape:Yellow SolidMolecular weight:630.817Revumenib
CAS:N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamideFormula:C32H47FN6O4SPurity:98%Molecular weight:630.82SNDX-5613
CAS:Revumenib, also known as SNDX-5613, is a potent and selective inhibitor of the interaction between menin and the lysine methyltransferase 2A (KMT2A). In recent studies, it has shown promising results in targeting the epigenetic regulator KMT2A, which seems to be involved in certain leukaemia subtypes.Formula:C32H47FN6O4SPurity:Min. 95%Molecular weight:630.8 g/mol






